A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.
H. S. Han
No relevant relationships to disclose
C. Swanton
Consultant or Advisory Role - Merck
Y. Y. Janjigian
Consultant or Advisory Role - Genentech
S. C. Sutherland
No relevant relationships to disclose
S. Chandarlapaty
Research Funding - Pfizer
R. Lehman
No relevant relationships to disclose
N. Hamilton
No relevant relationships to disclose
J. Knowles
Employment or Leadership Position - Merck
R. Lee
Employment or Leadership Position - Merck
L. Yan
Employment or Leadership Position - Merck
D. Sullivan
Research Funding - Merck
C. Hudis
Research Funding - Merck